3D OCT in Diabetic Macular Edema to Determine Response to Anti-VEGF Drug Therapy

3D OCT in Diabetic Macular Edema to Determine Response to Anti-VEGF Drug Therapy - 3D OCT in Diabetic Macular Edema to Determine Response to Anti-VEGF Drug Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047797

Enrollment

Registered

2022-05-18

Start date

2022-05-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. diagnosis of type 2 DM with center-involved DME 2. use of aflibercept or ranibizumab as anti-VEGF therapy for DME 3. macular thickening map image by OCT performed up to 1 month before anti-VEGF drug administration

Exclusion criteria

Exclusion criteria: 1. typical focal DME with ring-shaped hard exudate 2. other retinal diseases, such as retinal vein occlusion or uveitis 3. anti-VEGF therapy with focal/grid laser photocoagulation 4. excessively severe medial opacity that precluded fundal evaluation

Design outcomes

Primary

Measure	Time frame
Percentage decrease in retinal thickness by site at 1 month after treatment	—

Countries

Japan

Contacts

Public ContactYutaka Yamada

university of Fukui Hospital Ophthalmology

yyutaka@u-fukui.ac.jp0776-61-8403

Outcome results